Invion Ltd.

Invion Ltd.
Stock Exchange Australian Stock Exchange
EPS
AUD0
Market Cap
AUD82.51 M
Shares Outstanding
5.5 B
Public Float
1.43 B

Profile

Address
722 High Street
Melbourne Victoria (VIC) 3102
Australia
Employees -
Website http://www.inviongroup.com
Updated 07/08/2019
Invion Ltd. engages in the development of treatments for respiratory and autoimmune disease. It develops the following drug assets: nadolol, zafirlukast, and ala-Cpn10. The company was founded on October 11, 2000 and is headquartered in Chermside, Australia.

Financials

View All

Thian Chew
Chairman
Mitchell Glass
Executive Director & Chief Medical Officer